- Conditions
- Hepatitis, Chronic Active
- Interventions
- CPG10101, Control
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 14
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • New Orleans, Louisiana + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–40
of 40
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Gastrointestinal Carcinoid Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Regional Gastrointestinal Carcinoid Tumor
- Interventions
- PEG-interferon alfa-2b, bevacizumab, laboratory biomarker analysis
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hepatitis C
- Interventions
- Ribavirin, Peg interferon alfa 2b, induction therapy
- Drug
- Lead sponsor
- Brooke Army Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 610 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2010
- U.S. locations
- 1
- States / cities
- Fort Sam Houston, Texas
- Conditions
- Localized Osteosarcoma, Metastatic Osteosarcoma
- Interventions
- Cisplatin, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Methotrexate, Peginterferon Alfa-2b, Quality-of-Life Assessment, Questionnaire Administration, Therapeutic Conventional Surgery
- Drug · Biological · Other + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 5 Years to 40 Years
- Enrollment
- 1,334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2022
- U.S. locations
- 186
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 132 more
- Conditions
- Melanoma
- Interventions
- Temozolomide (TMZ), Pegylated Interferon Alpha-2b (PGI)
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Interventions
- PEG-interferon alfa-2b, PEG-interferon alfa-2b
- Biological · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Pegylated Alfa Interferon, sunitinib, erlotinib
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- HIV Infections, Hepatitis C
- Interventions
- Pegylated-Interferon Alfa 2b (PEG-IFN), Ribavirin (RBV), Boceprevir (BOC)
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 262 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 30 more
- Conditions
- Adult T-cell Leukemia-Lymphoma, ATLL
- Interventions
- Belinostat, Zidovudine, Interferon-Alfa-2b, Pegylated Interferon-Alfa-2b, Lymphodepleting Therapy
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Intraocular Melanoma, Melanoma (Skin)
- Interventions
- PEG-interferon alfa-2b, thalidomide
- Biological · Drug
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2007
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Chronic Hepatitis C
- Interventions
- Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin
- Drug
- Lead sponsor
- InterMune
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Brisbane, California
- Conditions
- Lymphoma
- Interventions
- Pegylated interferon α-2b, Psoralens with ultraviolet light A, Narrowband-ultraviolet light B
- Biological · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Chronic Hepatitis C
- Interventions
- Pegylated Interferon alfa-2b, Simeprevir, Ribavirin, Sofosbuvir
- Drug
- Lead sponsor
- Center For Hepatitis C, Atlanta, GA
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Non-Hodgkins Lymphoma
- Interventions
- CHOP/Rituximab, PEG INTRON
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 75 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2012
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- HIV Infections, Hepatitis C
- Interventions
- Ribavirin, Aldesleukin, Peginterferon alfa-2b
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2005
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 5 more
- Conditions
- Juvenile Pilocytic Astrocytomas, Optic Pathway Gliomas
- Interventions
- Pegylated interferon alpha-2b
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 3 Years to 25 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia